US Launch For Novartis' Valsartan
Novartis' AT1 blocker Diovan (valsartan) has been launched onto the USmarket for the treatment of hypertension. Valsartan is indicated for the first-line treatment of hypertension, and offers blood pressure control comparable to ACE inhibitors (eg lisinopril and enalapril) and an outstanding side-effect profile.
The drug was first launched in Germany last July, and is also available in the UK, Argentina and Switzerland. In addition, it has been approved for marketing in 15 other countries to date.
The recommended starting dose is 80mg once/day, and this may be increased to 160mg or 320mg/day, or a diuretic added, if additional hypotensive effect is required. Novartis is conducting a large-scale mega-trial of valsartan to see if its proven benefits in control of hypertension and good safety profile can translate to benefits in mortality rates. Furthermore, Phase III trials are ongoing to test the drug's activity in the treatment of patients with congestive heart failure.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze